Brain Advance Access published online on March 12, 2008
Brain, doi:10.1093/brain/awn016
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
1Department of Neurology, 2Department of Psychiatry, 3Department of Radiology and 4Department of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
Correspondence to:
Steven T. DeKosky, MD, Department of Neurology, 3471 Fifth Avenue, Suite 811, Pittsburgh, PA 15213, USA E-mail: dekoskyst{at}upmc.edu
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to β-pleated sheet aggregates of the amyloid-β (Aβ) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Aβ deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Aβ-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Aβ plaque load and peptide levels, [3H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Aβ42 or Aβ40, and to vascular Aβ deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Aβ plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular ‘ghost’ NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [3H]PiB binding and insoluble Aβ peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [3H]PiB binding, insoluble Aβ peptide levels, 6-CN-PiB- and Aβ plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Aβ deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Aβ plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Aβ plaque burden.
Key Words: Pittsburgh Compound-B; PiB; amyloid imaging; plaques; PET imaging
Abbreviations: Aβ, amyloid-β peptide; AC-PC, the plane of anterior comissure-posterior comissure; BA, Brodmann area; CAA, cerebral amyloid angiopathy; DVR, Logan distribution volume ratio; ELISA, enzyme linked immunoadsorbant assay; ERC, entorhinal cortex; FA, formic acid; IHC, immunohistochemistry; NFT, neurofibrillary tangles; PiB, Pittsburgh Compound-B; ROI, region-of-interest; Thio-S, thioflavin-S; VOI, volume-of-interest
Received October 28, 2007. Revised December 29, 2007. Accepted January 21, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D. Cohen, J. C. Price, L. A. Weissfeld, J. James, B. L. Rosario, W. Bi, R. D. Nebes, J. A. Saxton, B. E. Snitz, H. A. Aizenstein, et al. Basal Cerebral Metabolism May Modulate the Cognitive Effects of A{beta} in Mild Cognitive Impairment: An Example of Brain Reserve J. Neurosci., November 25, 2009; 29(47): 14770 - 14778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Umegaki Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing, November 16, 2009; (2009) afp211v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Migliaccio, F. Agosta, K. Rascovsky, A. Karydas, S. Bonasera, G. D. Rabinovici, B. L. Miller, and M. L. Gorno-Tempini Clinical syndromes associated with posterior atrophy: Early age at onset AD spectrum Neurology, November 10, 2009; 73(19): 1571 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Scheinin, S. Aalto, J. Koikkalainen, J. Lotjonen, M. Karrasch, N. Kemppainen, M. Viitanen, K. Nagren, S. Helin, M. Scheinin, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls Neurology, October 13, 2009; 73(15): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hedden, K. R. A. Van Dijk, J. A. Becker, A. Mehta, R. A. Sperling, K. A. Johnson, and R. L. Buckner Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden J. Neurosci., October 7, 2009; 29(40): 12686 - 12694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Visser and D. S. Knopman Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI Neurology, September 8, 2009; 73(10): 744 - 745. [Full Text] [PDF]
|
|
|
|
 |
|
 V L Villemagne, C A McLean, K Reardon, A Boyd, V Lewis, G Klug, G Jones, D Baxendale, C L Masters, C C Rowe, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry, September 1, 2009; 80(9): 998 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tolboom, W. M. van der Flier, M. Yaqub, R. Boellaard, N. A. Verwey, M. A. Blankenstein, A. D. Windhorst, P. Scheltens, A. A. Lammertsma, and B. N.M. van Berckel Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding J. Nucl. Med., September 1, 2009; 50(9): 1464 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nelissen, K. Van Laere, L. Thurfjell, R. Owenius, M. Vandenbulcke, M. Koole, G. Bormans, D. J. Brooks, and R. Vandenberghe Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease J. Nucl. Med., August 1, 2009; 50(8): 1251 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Ikonomovic, L. Wecker, E. E. Abrahamson, J. Wuu, S. E. Counts, S. D. Ginsberg, E. J. Mufson, and S. T. DeKosky Cortical {alpha}7 Nicotinic Acetylcholine Receptor and {beta}-Amyloid Levels in Early Alzheimer Disease Arch Neurol, May 1, 2009; 66(5): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koole, D. M. Lewis, C. Buckley, N. Nelissen, M. Vandenbulcke, D. J. Brooks, R. Vandenberghe, and K. Van Laere Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging J. Nucl. Med., May 1, 2009; 50(5): 818 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Jack Jr, V. J. Lowe, S. D. Weigand, H. J. Wiste, M. L. Senjem, D. S. Knopman, M. M. Shiung, J. L. Gunter, B. F. Boeve, B. J. Kemp, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain, May 1, 2009; 132(5): 1355 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Frisoni, M. Lorenzi, A. Caroli, N. Kemppainen, K. Nagren, and J. O. Rinne In vivo mapping of amyloid toxicity in Alzheimer disease Neurology, April 28, 2009; 72(17): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, N. Ayutyanont, J. Keppler, S. A. Reeder, J. B. S. Langbaum, et al. Fibrillar amyloid-{beta} burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease PNAS, April 21, 2009; 106(16): 6820 - 6825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. McNamee, S.-H. Yee, J. C. Price, W. E. Klunk, B. Rosario, L. Weissfeld, S. Ziolko, M. Berginc, B. Lopresti, S. DeKosky, et al. Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements J. Nucl. Med., March 1, 2009; 50(3): 348 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dhawan and D. Eidelberg Mom and me: Brain metabolism links Alzheimer disease to maternal genes Neurology, February 10, 2009; 72(6): 486 - 487. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Jalbert, L. A. Daiello, and K. L. Lapane Dementia of the Alzheimer Type Epidemiol. Rev., November 1, 2008; 30(1): 15 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Aizenstein, R. D. Nebes, J. A. Saxton, J. C. Price, C. A. Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B. E. Snitz, P. R. Houck, et al. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly Arch Neurol, November 1, 2008; 65(11): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist Arch Neurol, October 1, 2008; 65(10): 1281 - 1283. [Full Text] [PDF]
|
|
|
|
|
|
N.-W. Hu, I. M. Smith, D. M. Walsh, and M. J. Rowan Soluble amyloid-{beta} peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo Brain, September 1, 2008; 131(9): 2414 - 2424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Validation of PiB-PET Imaging in Alzheimer Disease Journal Watch Neurology, August 5, 2008; 2008(805): 6 - 6. [Full Text]
|
|